Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Captures Overall Composite Edge (37.1 SELL vs 53.2 HOLD), While CRMD Leads 4–2 on Growth & Valuation Pillars

TLPH Overall Winner 6-Pillar Tally: TLPH 2 – 4 CRMD Matrix Metrics: TLPH 5 – 5 CRMD

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (37.1/100 SELL vs. 53.2/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. TLPH trades at $0.86 (1.0x Forward P/E, -1474700.0% operating margin) versus CRMD at $4.92 (49.0x Forward P/E, 41.0% operating margin).

  • Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. 41.0% operating margin) and revenue trajectory (+0.0% vs. -47.7% YoY).
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs CRMD
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11

6-Pillar Scorecard Institutional Category Breakdown (TLPH 2 – 4 CRMD)

Columns: Metric · TLPH · CRMD
1. Valuation Multiples TLPH
Forward P/E 1.0x 49.0x
Trailing P/E 1.0x 2.4x
PEG Ratio N/M 3.79x
EV / Revenue N/M N/M
2. Growth & Scale CRMD
Revenue Growth (YoY) +0.0% -47.7%
Earnings Growth (YoY) +0.0% +6.7%
TTM Revenue (USD) $1,000 $1.05B
Market Cap $53.7M $384.7M
3. Profitability & Quality CRMD
Gross Margin N/A 87.4%
Operating Margin -1474700.0% 41.0%
Net Profit Margin 0.0% 15.5%
Return on Equity (ROE) -143.4% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) -$15M EBITDA $785M
Cash Flow Margin N/A 74.6%
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $535M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TLPH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 118.4% (100th %ile) 56.3% (25th %ile)
Put/Call OI Skew N/A 0.69x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity N/A 46.4% of Rev ($488M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (5) vs CRMD (5)
Institutional Metric TLPH CRMD Criterion Row Edge
Market Capitalization
Scale
$53.7M $384.7M Larger Scale CRMD
Trailing P/E Ratio
Valuation
1.0x 2.4x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x 49.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% -47.7% Higher Growth TLPH
Operating Margin (TTM)
Profitability
-1474700.0% 41.0% Higher Margin CRMD
Net Profit Margin
Profitability
0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
-143.4% 15.3% Higher ROE CRMD
52-Week Range Position
Momentum
20% ($1–$2) 3% ($5–$13) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 1.20β · 107% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 53.2 / 100 (HOLD) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $1.05B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.79x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) $785M ($535M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +12.01 pp
TLPH: -20.29% · CRMD: -32.3%
3M Horizon TLPH +10.99 pp
TLPH: -28.85% · CRMD: -39.84%
6M Horizon TLPH +45.84 pp
TLPH: +7.98% · CRMD: -37.86%
1Y Horizon TLPH +38.15 pp
TLPH: -18.01% · CRMD: -56.16%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs CRMD. Trailing 12-month operating profitability (TLPH -1474700.0% vs CRMD 41.0%) and valuation multiples (TLPH 1.0x vs CRMD 49.0x Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.05B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 49.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs CRMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (37.1/100 SELL vs. 53.2/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. TLPH trades at $0.86 (1.0x Forward P/E, -1474700.0% operating margin) versus CRMD at $4.92 (49.0x Forward P/E, 41.0% operating margin). Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. 41.0% operating margin) and revenue trajectory (+0.0% vs. -47.7% YoY). Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRMD leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $1.05B for CRMD. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.